| 2024/05/02 17:56:27 | |
|---|---|
| Price | |
| 3.4068 CHF | |
| Difference | 3.55% (0.12) |
General attributes
| ISIN | CH0256379097 |
| Symbol | MOLN |
| Exchange | London Stock Exchange |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 140 EUR |
| Benchmark | SWISS MARKET INDEX |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 3.4068 CHF |
| High | 3.4068 CHF |
| Low | 3.4068 CHF |
| Close (prev. day) | 3.29 CHF |
| VWAP | 3.4068 CHF |
| Volume (pcs) | 5,907 |
| Trading volume | 20,123.97 |
| Number of trades | 1 |
| Last size | 5,907 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: MOLECULAR PARTNERS AG |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/09/11 |
|
Global Equity Ratings |
|
| 2024/09/05 |
|
Global Equity Ratings |
|
| 2024/08/12 |
|
Global Equity Ratings |
|
| 2024/07/24 |
|
Global Equity Ratings |
|
| 2024/07/12 |
|
Global Equity Ratings |
|
| 2024/05/02 17:56:27 | |
|---|---|
| Price | |
| 3.4068 CHF | |
| Difference | 3.55% (0.12) |
General attributes
| ISIN | CH0256379097 |
| Symbol | MOLN |
| Exchange | London Stock Exchange |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 140 EUR |
| Benchmark | SWISS MARKET INDEX |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 3.4068 CHF |
| High | 3.4068 CHF |
| Low | 3.4068 CHF |
| Close (prev. day) | 3.29 CHF |
| VWAP | 3.4068 CHF |
| Volume (pcs) | 5,907 |
| Trading volume | 20,123.97 |
| Number of trades | 1 |
| Last size | 5,907 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | - | - | - |
| Perf (abs.) | - | - | - |
| Beta | 0.60 | 0.35 | 0.37 |
| Volatility | 24.53 | 22.99 | 10.57 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | - CHF (-) |
| Ø price 30 days | Ø volume 30 days (pcs.) | - CHF (-) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 3.3484 CHF (155) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 3.5949 CHF (366) |
| YTD High | date | 3.8938 CHF (2024/01/09) |
| YTD Low | date | 3.2900 CHF (2024/04/30) |
| 52 Weeks High | date | 4.0030 CHF (2023/11/13) |
| 52 Weeks Low | date | 3.2900 CHF (2024/04/30) |
All listings for MOLECULAR PARTNERS AG
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Stuttgart | 2019/06/28 | 15:43 | 12.90 EUR | 0.00 | 7 |
| SIX Swiss Exchange | 2024/09/27 | 14:59 | 4.435 CHF | 0.06 | 103 |
| London Stock Exchange | 2024/05/02 | 17:56 | 3.4068 CHF | 0.02 | 1 |
| Frankfurt | 2019/06/28 | 08:03 | 12.88 EUR | 0.00 | 2 |
| FINRA other OTC Issues | 2024/07/24 | 15:30 | 5.89 USD | 0.00 | 2 |
| Berlin | 2019/06/28 | 15:59 | 12.90 EUR | 0.00 | 5 |
Company Logo
Contact Details
| MOLECULAR PARTNERS AG |
| - - |
| Wagistrasse 14 - 8952 Schlieren |
| Telefon: +41-44-755-77-00 |
| Fax: +41-44-755-77-07 |
| E-mail: info@molecularpartners.com |
PDF Downloads
| Company report: MOLECULAR PARTNERS AG | |
Company Profile
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland. |
Members of Management Board
| Patrick Amstutz | Chairman of Managing Board |
| Michael Tobias Stumpp | Member of Executive Committee |
| Alexander Zürcher | Member of Executive Committee |
| Philippe Legenne | Member of Executive Committee |
| Renate Gloggner | Member of Executive Committee |
Board of directors
| Agnete Brunsvik Fredriksen | Member of the administrative board |
| Dominik Höchli | Member of the administrative board |
| Michael Vasconcelles | Member of the administrative board |
| Steven Holtzman | Member of the administrative board |
| Vito Palombella | Member of the administrative board |
| Sandipkumar S. Kapadia | Member of the administrative board |
| William Burns | Chairman of the administrative boar |